FindTrial
Sign In

C1-esterase inhibitor

DRUG7 trials

Sponsors

Octapharma Pharmazeutika Produktionsgesellschaft mbH, Johann Wolfgang Goethe University Hospital, Radboud University Medical Center, UMC Utrecht, CSL Behring

Conditions

Antibody-mediated RejectionEndotoxemiaHereditary AngioedemaHereditary Angioedema Types I and IIInflammationInnate Immune ResponseMulti Organ Dysfunction SyndromeMultiple Organ Dysfunction Syndrome

Phase 3

Berinert P Study of Subcutaneous Versus Intravenous Administration
CompletedNCT00748202
Johann Wolfgang Goethe University HospitalHereditary Angioedema
Start: 2008-09-30End: 2010-12-31Updated: 2011-01-19
Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture
TerminatedNCT01275976
UMC UtrechtInflammation, Multiple Organ Dysfunction Syndrome, Sepsis +1
Start: 2012-04-30End: 2015-02-28Updated: 2015-02-04
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II
CompletedNCT01766414
Radboud University Medical CenterEndotoxemia, Inflammation, Innate Immune Response +1
Start: 2013-09-30End: 2014-01-31Updated: 2014-12-02
A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
CompletedNCT02316353
CSL BehringHereditary Angioedema Types I and II
Start: 2014-12-31End: 2017-09-21Updated: 2018-11-14
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
TerminatedNCT03221842
CSL BehringAntibody-mediated Rejection
Start: 2017-11-06End: 2021-01-20Updated: 2022-07-29
Prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety phase 3 study of an intravenous human plasma-derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks
RecruitingCTIS2023-503507-29-00
Octapharma Pharmazeutika Produktionsgesellschaft mbHacute hereditary angioedema attacks
Start: 2024-04-30Target: 6Updated: 2025-02-05

Unknown Phase

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia
CompletedNCT00785018
Radboud University Medical CenterEndotoxemia, Inflammation, Multi Organ Dysfunction Syndrome
Start: 2008-11-30End: 2009-08-31Updated: 2011-04-22

Related Papers

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
2021-02-1524 citations
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial.
2020-02-0413 citations
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
2019-02-1557 citations
Human CD62Ldim neutrophils identified as a separate subset by proteome profiling and in vivo pulse-chase labeling
Blood2017-05-18110 citations